Ibandronate: Its Role in Metastatic Breast Cancer
|
|
- Clarence Booth
- 5 years ago
- Views:
Transcription
1 Ibandronate: Its Role in Metastatic Breast Cancer David Cameron, a Marie Fallon, a Ingo Diel b a Western General Hospital, Edinburgh, United Kingdom; b Institute for Gynecological Oncology, Mannheim, Germany Key Words. Bisphosphonates Ibandronate Bone metastases Bone pain Safety Efficacy Abstract Bisphosphonates are the most effective agents for treating and/or preventing complications of bone metastases and are the standard of care in this setting. Currently, four bisphosphonates are available for metastatic bone disease (MBD): clodronate, pamidronate, zoledronic acid, and ibandronate. Although all four of these bisphosphonates have been shown to reduce the incidence of skeletal-related events in patients with bone metastases, there are substantial differences among these agents in their potency, dose and route of administration, and side effects. Ibandronate and zoledronic acid, the two newer aminobisphosphonates, appear to have similar biochemical efficacies when phase III trial data are compared. Both agents were equally effective in reducing markers of bone resorption in the only Correspondence: David Cameron, M.D., Department of Oncology, Western General Hospital, Crewe Road, Edinburgh, EH 2XU United Kingdom. Telephone: ; Fax: ; david.cameron@ed.ac.uk Received June 13, 2006; accepted for publication June 21, AlphaMed Press /2006/$20.00/0 The Oncologist 2006;11(suppl 1): prospective comparative trial carried out to date, but no data on relative clinical efficacy are available from headto-head comparisons. Both the oral and i.v. formulations of ibandronate have also shown long-term efficacy in managing metastatic bone pain (MBP), but the onset of action of standard bisphosphonate treatment is not sufficient when rapid relief of pain is required. Because of its favorable renal safety profile, i.v. ibandronate can be administered daily for 3 days, as a so-called loading dose. This dosing regimen has allowed rapid and effective relief of MBP without the unwanted side effects associated with opioids and other analgesics. Ibandronate is thus an effective, flexible, and well-tolerated bisphosphonate that can meet the varying requirements of patients with MBD. The Oncologist 2006;11(suppl 1):27 33 Introduction Bone metastasis is a significant debilitating feature of many advanced cancers, particularly breast and prostate cancer, where up to 75% of patients will experience bone metastasis [1]. Although the presence of bone metastases generally indicates that the cancer cannot be cured, many patients may live for several years: in patients with advanced breast cancer, the median survival time after the diagnosis of bone metastases is approximately 2.5 years [2, 3]. The morbidity associated with metastatic bone disease (MBD), including pain and fracture risk, means that effective treatment is essential to allow patients to live as normally as possible. Bisphosphonates are the most effective agents for preventing complications of bone metastases and are the standard of care in this setting. Currently, four bisphosphonates are available for MBD: clodronate (Bonefos ; Schering AG, Berlin; and Ostac, Loron, F. Hoffmann-La Roche Ltd, Basel, Switzerland), pamidronate (Aredia ; Novartis Pharmaceuticals Corporation, East Hanover, NJ), zoledronic acid (Zometa ; Novartis Pharmaceuticals Corporation), and ibandronate (Bondronat ; F. Hoffmann-La Roche Ltd). All four have been shown to be effective against skeletal complications, but their activities are by no means identical, and there may be substantial differences among the bisphosphonates in their biology as well as mode of administration, convenience, and tolerability. It is therefore appropriate to consider what patients require from bisphosphonate treatment and how different bisphosphonates may meet these requirements.
2 28 Ibandronate in Metastatic Breast Cancer The primary requirement for any bisphosphonate is that it should be effective in treating and preventing skeletal complications because this is the principal reason for administration. Assuming this essential efficacy criterion is met, however, the ability to alleviate bone pain in a rapid and sustained fashion is also an important consideration. Bone pain is experienced by 60% 80% of patients and has a major impact on quality of life []. Other important issues in bisphosphonate therapy include effects on mobility and function, allowing patients to resume or continue their normal lives, and differences in tolerability and administration schedules, which can have significant impact on patient quality of life in terms of compliance and convenience. This review considers the efficacy and tolerability of i.v. and oral ibandronate in these contexts. The Efficacy of Ibandronate in Reducing Skeletal-Related Events The efficacy of ibandronate in reducing skeletal complications of MBD has been demonstrated in three randomized, placebo-controlled phase III trials in patients with breast cancer and bone metastases. i.v. ibandronate was assessed in one trial, and oral ibandronate was assessed in the other two. In each trial, ibandronate reduced the risk of new bone complications by approximately 0%. In the trial of i.v.-administered ibandronate, 312 patients with bone metastases resulting from breast cancer were randomized to receive either ibandronate (6 mg) or placebo every 3 weeks for up to 2 years. New bone complications were defined as any of the following: vertebral fractures, pathological nonvertebral fractures, radiotherapy, or surgery for bone pain or impending fractures. The primary efficacy parameter was the skeletal morbidity period rate (SMPR), which was calculated as the number of 12-week periods in which new bone complications occurred divided by the total observation time (in 12-week periods). The SMPR allows for the fact that bone events occurring close together are frequently related and thus avoids multiple counting of such related events. Patients in the 6-mg ibandronate group had a significantly lower SMPR than patients in the placebo group (1.19 vs. 1.8; p =.00) [5]. The mean number of new bone events per patient was also significantly lower (2.65 vs. 3.6; p =.032), and the time to first new bone event was significantly longer in the ibandronate group (50.6 weeks vs weeks; p =.018). A multivariate Poisson regression analysis showed that the risk for a new bone event was 0% lower for patients in the 6-mg ibandronate group [6]. For oral ibandronate, the two identical trials were analyzed together, as specified and preplanned in the trial protocols [7]. In total, 56 patients were randomized to receive oral ibandronate (50 mg) or placebo daily for up to 2 years. The primary efficacy parameter was the SMPR. Patients in the 50-mg ibandronate group had a significantly lower SMPR than those in the placebo group (0.95 vs. 1.18; p =.00). The mean number of events per patient was also significantly lower (1.15 vs. 1.85; p =.008). A multivariate Poisson regression analysis showed that the risk for a new bone event was 38% lower for patients in the 50-mg ibandronate group. These three trials established that both i.v. and oral ibandronate were effective in reducing skeletal-related events (SREs) in patients with metastatic breast cancer, and both formulations were approved for this indication in the European Union in Currently, there are no randomized prospective data comparing the efficacy of ibandronate in reducing skeletal events with the efficacies of other bisphosphonates used for the treatment of MBD. Such trials are currently underway (see below) but will take some years to complete. However, a comparison of oral ibandronate and i.v. zoledronic acid has been conducted using markers of bone turnover as a surrogate measure of bisphosphonate SRE efficacy [8]. Serum concentrations of bone turnover markers, such as crosslinked collagen C-terminal telopeptide (CTX), reflect the rate of bone resorption, and this has been shown to be predictive for the incidence of SREs [9 11]. In an open-label, 12-week study in patients with breast cancer and bone metastases, serum CTX was decreased by 76% in patients treated with ibandronate and by 73% in patients treated with zoledronic acid (Fig. 1) [8]. Similar results were obtained for other bone markers, such as bone alkaline phosphatase, amino-terminal procollagen propeptides, and osteocalcin, indicating that ibandronate and zoledronic acid have comparable effects on bone turnover. Subgroup analyses also demonstrated that the effects of the two bisphosphonates were similar in patients with high, Figure 1. Reduction in serum C-terminal telopeptide (S-CTX), a marker of bone turnover, by ibandronate and zoledronic acid. The Oncologist
3 Cameron, Fallon, Diel 29 medium, or low levels of bone markers at baseline [8]. This is the first trial to compare the newer bisphosphonates ibandronate and zoledronic acid and suggests comparable bone marker efficacy. Moreover, available data suggest that ibandronate and zoledronic acid may also be comparable in terms of SRE efficacy. In a randomized, placebo-controlled, phase III trial in 228 patients with breast cancer and bone metastases, zoledronic acid reduced the frequency of SREs [12]. The skeletal event rate was calculated as the number of skeletal events divided by time on study, and the primary efficacy end point in that study was the SRE ratio between treatment groups, that is, the SRE rate in the zoledronic acid group divided by the SRE rate in the placebo group. The SRE ratio (adjusted for patients with prior fracture) was 0.61, indicating that zoledronic acid reduced the frequency of SREs by 39%. According to Andersen-Gill multiple-event analysis, zoledronic acid reduced the overall risk of experiencing an SRE by 1%. Tripathy and Budde [13] reported similar risk reductions for ibandronate when the data from the pivotal trials were reanalyzed using the Andersen-Gill method. i.v. ibandronate was associated with a risk reduction of 29% (p =.0183), while oral ibandronate reduced the risk for an event by 38% (p <.0001). Such cross-trial comparisons naturally need to be treated with caution because patient populations, end points, and protocols may differ widely between trials. Nevertheless, in the absence of prospective, randomized data for prevention of SREs, current evidence and data using markers of bone turnover as a surrogate for clinical efficacy suggest that zoledronic acid and ibandronate are likely to have comparable efficacy for preventing SREs. Two large, randomized, phase III trials comparing oral ibandronate with i.v. zoledronic acid are currently under way, one in the U.S. and one in the United Kingdom. The U.S. trial, conducted by the Southwest Oncology Group (SWOG; trial S0308), is randomizing 88 patients with breast cancer and bone metastases to oral ibandronate (50 mg/day) or zoledronic acid ( mg) by i.v. infusion every weeks, both for 18 months [1]. The primary end point is the proportion of patients suffering new SREs, with secondary end points including time to first SRE, quality of life assessments, overall survival, and safety. The UK National Cancer Research Network trial is known as ZICE (zoledronic acid vs. oral ibandronate comparative evaluation). A total of 1,00 patients will be randomized to 50-mg oral ibandronate or -mg i.v. zoledronic acid for 2 years [15]. The primary end point of the ZICE trial is the frequency and timing of SREs during the 2-year treatment period. Secondary end points include the proportion of patients experiencing new SREs, time to first SRE, quality of life, resource utilization, and safety. Both of these trials are designed to determine noninferiority, that is, if ibandronate has at least equal efficacy to zoledronic acid in reducing SREs. If this can be shown, physicians will be able to prescribe the most appropriate bisphosphonate based on other factors such as safety, convenience, and quality of life without any concern that the choice of an oral agent could compromise efficacy. Relief of Metastatic Bone Pain The phase III trials of i.v. and oral ibandronate included assessments of bone pain using patient-reported pain scores. In both studies, patients in the ibandronate arm experienced significantly lowered pain scores throughout the 2 years of treatment (Fig. 2) [16, 17]. The shape of the curves were remarkably similar for the oral and i.v. formulations, with maximum pain relief achieved at 12 weeks then maintained below baseline throughout the study period in each case. This was also reflected in quality of life assessments, with similar improvements in quality of life (European Organization for Research and Treatment of Cancer Quality of Figure 2. Long-term relief of metastatic bone pain over 2 years with i.v (A) [16] or oral (B) [17] ibandronate.
4 30 Ibandronate in Metastatic Breast Cancer Life Questionnaire C30) observed in both trials. Oral and i.v. ibandronate thus appear equally effective in achieving long-term relief of metastatic bone pain (MBP) and improving quality of life. However, because maximum pain relief is not achieved until 12 weeks, acute, moderate-to-severe bone pain may not be alleviated in a timely manner with standard ibandronate therapy, or indeed with other bisphosphonates. Rapid pain relief with intensive dosing schedules of ibandronate has been investigated in three phase II studies. Mancini et al. [18] showed that, in patients with opioidresistant bone pain, intensive ibandronate therapy ( mg for consecutive days, total 16 mg) provided significant analgesic effects and was well tolerated. Two studies in patients with urologic cancer or prostate cancer have examined the effects of intensive dosing followed by standard maintenance therapy [19, 20]. In those trials, i.v. ibandronate was administered as a loading dose (6 mg on 3 consecutive days) followed by 6 mg every weeks for 20 weeks. In the urologic cancer study, >80% of patients had at least a three-point reduction in bone pain assessed by visual analogue scale, with maximum pain relief achieved by day 3 [20]. In addition, 25% of patients became totally pain free. Functional capacity increased so markedly that patients who were previously bedridden reported increased mobility within 1 week of starting their bisphosphonate. Similar results were observed in the prostate cancer trial [19]. Loading-dose ibandronate is now being evaluated in phase III randomized trials in patients with moderate-tosevere bone pain. Because oral and i.v. ibandronate are equally effective in long-term relief of MBP, two trials are being conducted (Bon-O-Pain/BO and Bon-I-Pain/ BO 1800) [21] using either oral or i.v. maintenance therapy after the initial loading dose [22]. The comparator arm in both trials is zoledronic acid every weeks (Fig. 3). It is not possible to give zoledronic acid as a loading dose on consecutive days because of safety considerations, in particular, renal toxicity (see below). The trials are blinded, and therefore treatment with placebo infusions or tablets will be given in parallel where appropriate to maintain blinding. Safety of Ibandronate and Other Bisphosphonates Because bisphosphonate therapy for MBD is generally palliative in patients with bone metastases, tolerability is a very important consideration. Adverse events (AEs) vary among different bisphosphonates and between different routes of administration. The main AEs associated with bisphosphonate therapy are acute-phase reactions, gastrointestinal toxicity, renal toxicity, and a rare but severe effect associated with some bisphosphonates, osteonecrosis of the jaw (ONJ). Acute-Phase Reactions Acute-phase reactions cover a spectrum of flu-like symptoms, joint pain, pyrexia, and other reactions that may occur following an i.v. infusion. These reactions are generally transient, lasting up to 1 2 days, and are more commonly associated with the first infusion. Two trials have assessed the safety of ibandronate in comparison with zoledronic acid. In the first trial, 77 patients with metastatic breast cancer or multiple myeloma were treated with i.v. ibandronate (6 mg on day 1) followed by oral ibandronate (50 mg daily from day 2), or i.v. zoledronic acid ( mg every 3 weeks) [22]. The second trial compared oral ibandronate (50 mg daily) with i.v. zoledronic acid ( mg every 3 weeks) in 27 patients with metastatic breast cancer [8]. In both studies, the overall incidence of AEs was lower for patients receiving ibandronate, particularly the incidence of pyrexia and flu-like symptoms on days 1 3 (Fig. ) [8, 23]. As expected, fewer patients on oral treatment experienced pyrexia and flu-like symptoms than patients on zoledronic acid (2% vs. 27%) [8]. However, only 13% of patients in the i.v. ibandronate arm experienced symptoms, compared with 26% in the zoledronic acid arm [23]. Gastrointestinal Effects Gastrointestinal AEs have been associated with oral bisphosphonate treatment, particularly clodronate, because of the large tablet size and dosing regimen (up to 2,00 mg Figure 3. The Bon-I-Pain and Bon-O-Pain clinical trials of loading-dose ibandronate for metastatic bone pain: study design [21]. Abbreviation: q3 w, every 3 weeks. The Oncologist
5 Cameron, Fallon, Diel 31 Figure. Pyrexia or flu-like symptoms reported as adverse events on days 1 3 following ibandronate or zoledronic acid treatment [8, 23]. daily in two doses) [2]. This has led to compliance difficulties in patients on long-term therapy. However, in phase III trials of oral ibandronate, the incidence of gastrointestinal AEs was reported as very low [7]. Patients in these studies were also permitted to continue receiving oral ibandronate for a further 2 years after the 2-year study period. Follow-up of these patients revealed a similar AE profile to that of the main study, and there were no withdrawals resulting from AEs in the extension period [25], indicating that gastrointestinal and other AEs remained low when oral ibandronate was administered for up to years. ONJ ONJ is a relatively recently described AE involving exposure of the bone of the maxilla and spontaneous loss of teeth, primarily after long-term exposure to bisphosphonates [26, 27]. Current data suggest that ONJ may occur more frequently in patients treated long term with zoledronic acid than with pamidronate [28, 29]. The pathophysiology of ONJ is not yet fully understood, but patients on long-term bisphosphonate therapy should be monitored for the condition. A dental examination should be considered prior to treatment, and patients should avoid elective jaw surgery. There have been 18 reports of ONJ in the 720,000 patients treated with ibandronate since 1996, and the majority of these patients had also been treated with another bisphosphonate [30]. Thus ONJ appears to be an infrequent AE with ibandronate therapy but, because of the relatively recent identification of the condition, the true frequency has not yet been established. Renal Safety The i.v. bisphosphonates pamidronate and zoledronic acid have been associated with instances of acute and chronic nephrotoxicity [31 36]. Renal damage is associated with high doses and short infusion times, particularly in the case of zoledronic acid, where an 8 mg dose evaluated in phase III trials was discontinued because of the degree of renal toxicity [37 39]. Labeling for zoledronic acid now prohibits the use of doses higher than mg, and serum creatinine must be measured before starting treatment, with dose reductions for those with evidence of renal impairment at baseline [0, 1]. Renal toxicity may not be a class effect of i.v. bisphosphonates. In phase III trials and later follow-up, there were no differences in renal toxicity between the ibandronate (administered via 60-minute infusions) and placebo groups. Patients treated with i.v. ibandronate experienced renal toxicity only to the same degree as those given placebo [22, 2]. In a study in 29 elderly patients with multiple myeloma, 25 of whom had renal impairment at baseline, i.v. ibandronate treatment did not result in significant changes in serum creatinine or other markers of renal damage [3]. The lack of renal toxicity associated with i.v. ibandronate means that, in contrast to zoledronic acid, the recommended 6-mg dose does not need to be adjusted for patients with renal impairment. Even when administered as a loading dose, no impairment of renal function was reported with ibandronate [20]. Based on its excellent renal safety profile, a rapid (15-minute) infusion of ibandronate is currently being evaluated. The results are expected toward the end of Loading-Dose Ibandronate: A Case History The use of loading-dose ibandronate for relief of MBP features in the following case history, which provides an example of how loading-dose ibandronate may fit into strategies for pain relief. The patient was a female, 63-year-old, retired swimming instructor with breast cancer and symptomatic bone metastases in the pelvis and femora. Previously a very fit and independent woman, her MBP was preventing her from leading a normal life. Her average pain score at rest was only 1/, but on movement this rose to 8/. On response to Brief Pain Inventory questionnaires, she reported pain as completely interfering with general activity, walking ability, normal work, and enjoyment of life. The use of opioids for pain relief was itself causing problems because these drugs were making her unacceptably sedated, and she had stopped using oral morphine for breakthrough pain. The patient was given loading-dose ibandronate (3 6 mg on days 1 3). At day 3, ibandronate therapy was associated with a meaningful impact on her quality of life, and the patient was able to resume normal activities of daily living (Table 1). There is clearly an unmet need for relief of MBP without the unwanted side effects of morphine and other opioids, especially for difficult-to-treat, spontaneously
6 32 Ibandronate in Metastatic Breast Cancer Table 1. Patient case history: Brief Pain Inventory responses before and after loading-dose ibandronate Question Before loading dose Worst pain in the past 2 hours 8/ 2/ % pain relief in past 2 hours 0% 80% In the past 2 hours, has pain interfered with: (0 = does not interfere, = completely interferes) General activity Mood Walking ability Normal work Relations with other people Sleep Enjoyment of life After loading dose (day 3) occurring exacerbations in pain, pain on movement, and breakthrough pain. Large-scale phase III trials of loading-dose ibandronate are now underway to determine the optimal use of this strategy in patients with moderate-tosevere bone pain. Discussion Bisphosphonates are the standard treatment for patients with MBD, and four bisphosphonates pamidronate, clodronate, zoledronic acid, and ibandronate are currently available for this indication. Although all four of these bisphosphonates have been shown to reduce the incidence of SREs in patients with bone metastases, there are substantial differences among these agents in their potency, dose and route of administration, and side effects. References Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27: Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer 2000;1: Domchek SM, Younger J, Finkelstein DM et al. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000;89: Bonica JJ. Management of cancer pain. Acta Anaesthesiol Scand Suppl 1982;7: Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;1: Body JJ, Kanis J, Diel I et al. Risk reductions in metastatic breast cancer: multivariate Poisson regression analyses of oral and i.v. ibandronate. Proc Am Soc Clin Oncol 2003;22: Ibandronate and zoledronic acid, the two newer aminobisphosphonates, appear to have similar efficacies when phase III trial data are compared. Both agents were equally effective in reducing markers of bone resorption in the only prospective comparative trial carried out to date. The results of ongoing, randomized, phase III comparisons are required before firm conclusions can be drawn on their relative efficacy in reducing SREs. The two bisphosphonates do differ markedly in other aspects, notably, the availability of both oral and i.v. ibandronate formulations that have equal efficacy and ibandronate s favorable safety profile. Ibandronate has also shown long-term efficacy in managing MBP, but the onset of action of standard bisphosphonate treatment is not sufficient when rapid relief of pain is required. Because of its renal safety profile, i.v. ibandronate can be administered as a loading dose. This dosing regimen has allowed rapid and effective relief of MBP without the unwanted side effects associated with opioids and other analgesics. Ibandronate is thus an effective, flexible, and well-tolerated bisphosphonate that can meet the varying requirements of patients with MBD. Acknowledgment The authors would like to thank Andrew Richardson for medical writing support during the preparation of the manuscript. Disclosure of Potential Conflicts of Interest D. C. has acted as a consultant for Roche and Novartis. I. D. has acted as a consultant for Roche and Schering and has received support from Roche, Novartis, Schering, Astra- Zeneca, Amgen, and Medac. M. F. has acted as a consultant for Roche. 7 Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 200;90: Body JJ, Lichinitser M, Tjulandin S et al. Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety data. Bone 2006;38(suppl 1):S69. 9 Brown JE, Thomson CS, Ellis SP et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89: Brown JE, Cook RJ, Major P et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97: Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23: The Oncologist
7 Cameron, Fallon, Diel Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23: Tripathy D, Budde M. Assessing the efficacy of ibandronate for the prevention of skeletal-related events (SREs) in metastatic bone disease: a methodological comparison. Bone 200;3(suppl 1):S91. 1 Rivkin S. Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: the SWOG trial. Bone 2006;38(suppl 1):S Barrett-Lee P, Murray N. Zoledronic acid versus ibandronate comparative evaluation in breast cancer patients with bone metastases: the NCRI ZICE trial. Bone 2006;38(suppl 1):S Diel IJ, Body JJ, Lichinitser MR et al. Improved quality of life after longterm treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 200;0: Body JJ, Diel IJ, Bell R et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 200;111: Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 200;22: Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002;5: Heidenreich A, Ohlmann C, Olbert P et al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 2003;1(suppl 5):S Body JJ, Gralow J, Bergström B. Loading-dose ibandronate with maintenance dosing for the palliation of metastatic bone pain: the Bon-I-Pain and Bon-O-Pain trials. Bone 2006;38(suppl 1):S Body JJ, Diel IJ, Tripathy D et al. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care 2006;15: Bergström B, Lichinitser M, Body JJ. Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: evidence from comparative phase II/III trials. Bone 2006;38(suppl 1):S68. 2 Paterson AH, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11: McLachlan SA, Cameron D, Murray R et al. Safety of oral ibandronate in the treatment of bone metastases from breast cancer. Clin Drug Invest 2006;26: Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61: Ruggiero SL, Mehrotra B, Rosenberg TJ et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 200;62: Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353: Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23: Chukwujindu J, Dolin P. Bisphosphonates and jaw osteonecrosis: updated experience with ibandronate. Presented at the 31st European Society for Medical Oncology Congress, Istanbul, Turkey, September 29 to October 3, Markowitz GS, Appel GB, Fine PL et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12: Markowitz GS, Fine PL, D agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 2002;39: Desikan R, Veksler Y, Raza S et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 2002;119: Buysschaert M, Cosyns JP, Barreto L et al. Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant 2003;18: Jones SG, Dolan G, Lengyel K et al. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. Br J Haematol 2002;119: Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;39: Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21: Rosen LS, Gordon DH, Dugan W Jr et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 200;0: Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 200;96: Novartis Pharmaceuticals Corporation. Zometa (zoledronic acid). US summary of product characteristics. East Hanover, NJ: Novartis Pharmaceuticals Corporation, November, Novartis International AG. Zometa (zoledronic acid). EU summary of product characteristics. Basel, Switzerland: Novartis International AG, May, Bell R, Diel IJ, Body JJ et al. Renal safety of ibandronate in patients with bone metastases from breast cancer: phase III trial results. EJC Suppl 200;2: Henrich D, Berner R, Hoffman M et al. Open-label study of ibandronate in elderly myeloma patients with pre-existing renal deterioration. Blood 2005;6:11.
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Richard Bell The Andrew Love Cancer Centre Cancer Services, Medical Oncology, Geelong, Victoria, Australia Key Words. Bisphosphonate
More informationBisphosphonate Treatment Recommendations for Oncologists
Bisphosphonate Treatment Recommendations for Oncologists Roger von Moos Rätisches Kantons- und Regionalspital, Chur, Switzerland Key Words. Bisphosphonates Ibandronate Renal safety Product labeling Product
More informationThe Role of Bisphosphonates in Early Breast Cancer
The Role of Bisphosphonates in Early Breast Cancer Alexander H.G. Paterson Tom Baker Cancer Centre and University of Calgary, Calgary, Alberta, Canada Key Words. Bisphosphonates Bone metastases Adjuvant
More informationRipamonti C, et al. ASCO 2012 (Abstract 9005)
ZOOM: A Prospective, Randomized Trial of Zoledronic Acid for Long-term Treatment in Patients With Bone-Metastatic Breast Cancer After 1 Year of Standard Zoledronic Acid Treatment D. Amadori, M. Aglietta,
More informationToo Much, Too Little, Too Late to Start Again? Assessing the Efficacy of Bisphosphonates in Patients with Bone Metastases from Breast Cancer
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Breast Cancer Too Much, Too Little, Too Late to Start Again?
More informationDepartment of Oncology and Hematology, University Hospital, Modena, Italy. 2. Explain the renal effects of long-term i.v. bisphosphonate treatment.
The Oncologist Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens PIERFRANCO CONTE, VALENTINA GUARNERI Department of Oncology and Hematology, University Hospital, Modena,
More informationScottish Medicines Consortium
Scottish Medicines Consortium zoledronic acid 5mg/100ml solution for infusion (Aclasta) No. (317/06) Novartis 8 September 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationManaging Metastatic Bone Pain: The Role of Bisphosphonates
462 Journal of Pain and Symptom Management Vol. 33 No. 4 April 2007 Review Article Managing Metastatic Bone Pain: The Role of Bisphosphonates Julie Gralow, MD, and Debu Tripathy, MD University of Washington
More informationGUIDELINES ON THE USE OF BISPHOSPHONATES IN PALLIATIVE CARE. November 2007(Amended July 2008)
Yorkshire Palliative Medicine Clinical Guidelines Group GUIDELINES ON THE USE OF BISPHOSPHONATES IN PALLIATIVE CARE November 2007(Amended July 2008) Authors: Dr Kath Lambert and Dr Liz Brown, on behalf
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 11 April 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 11 April 2012 XGEVA 120 mg, solution for injection 1 glass vial of 120 mg/1.7 ml (CIP code: 217 253-8) 4 glass vials
More informationOncologist. The. Academia Pharma Intersect: Symptom Management and Supportive Care
The Oncologist Academia Pharma Intersect: Symptom Management and Supportive Care Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases MATTI AAPRO, a FRED SAAD, b LUIS
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationPreclinical Perspectives on Bisphosphonate Renal Safety
Preclinical Perspectives on Bisphosphonate Renal Safety Jean-Jacques Body, a Thomas Pfister, b Frieder Bauss c a Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; b Pre-clinical
More informationKey Words. Biologic markers Breast neoplasms Survival rate Zoledronic acid
The Oncologist Breast Cancer Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity ALLAN LIPTON, a RICHARD J. COOK, b PIERRE MAJOR, c MATTHEW
More informationManaging Skeletal Metastases
School of Breast Oncology 2012 Managing Skeletal Metastases Cathy Van Poznak, MD Assistant Professor University of Michigan Comprehensive Cancer Center Saturday, November 3, 2012 Learning Objectives: Define
More informationManagement of Bone Metastasis in Breast Cancer: Drugs, Dosing and Duration
Management of Bone Metastasis in Breast Cancer: Drugs, Dosing and Duration Kara Laing, MD, FRCPC Chair and Associate Professor, Discipline of Oncology Memorial University of Newfoundland Medical Oncologist,
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 119 No 1246 ISSN 1175 8716 Osteonecrosis of the jaw and bisphosphonates putting the risk in perspective Mark Bolland, David Hay, Andrew Grey, Ian Reid, Tim Cundy Abstract
More informationBisphosphonates, inhibitors of osteoclasts, have
ABSTRACT Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy Strategies for prevention and early recognition MAICO D. MELO, D.M.D.; GEORGE OBEID, D.D.S. Bisphosphonates,
More informationNovel therapies for Myeloma bone disease. Dr. Naif AlJohani ABIM,FRCPC Adult Hematology/BMT King Faisal specialist hospital & Research center Jeddah
Novel therapies for Myeloma bone disease Dr. Naif AlJohani ABIM,FRCPC Adult Hematology/BMT King Faisal specialist hospital & Research center Jeddah 1 Introduction Multiple myeloma (MM) is a plasma cell
More informationDental Issues In Cancer Patients Using Bone Modifying Agents What Every GPO Must Know
Dental Issues In Cancer Patients Using Bone Modifying Agents What Every GPO Must Know Dr. Allan Hovan, DMD, MSD, FRCD (C) 2016 CAGPO Annual Meeting Four Seasons Hotel, Vancouver, B.C. Sunday, October 2
More informationA Case of Acquired Fanconi Syndrome Induced by Zoledronic Acid
CASE REPORT A Case of Acquired Fanconi Syndrome Induced by Zoledronic Acid Tetsuhiro Yoshinami, Toshinari Yagi, Daisuke Sakai, Naotoshi Sugimoto and Fumio Imamura Abstract A 61-year-old woman with metastatic
More informationBone metastases in hematology
Botziekte bij hematologische tumoren Prof. Dr. Michel Delforge Hematologie, UZ Leuven Bone metastases in hematology The bone marrow is the source of many hematological malignancies However, bone damage
More informationBone metastases of solid tumors Diagnosis and management by
Bone metastases of solid tumors Diagnosis and management by Dr/RASHA M Abd el Motagaly oncology consultant Nasser institute adult oncology unit 3/27/2010 1 Goals 1- Know the multitude of problem of bone
More informationOncologist. The. Symptom Management and Supportive Care. Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid
The Oncologist Symptom Management and Supportive Care Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid JAMES BERENSON, a RAIMUND HIRSCHBERG b a Cedars-Sinai Medical Center, Los Angeles,
More informationEfficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with Advanced Cancer
Review Articles Jpn J Clin Oncol 2012;42(8)663 669 doi:10.1093/jjco/hys088 Advance Access Publication 13 June 2012 Efficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with
More information2. Explain the importance of infusion time on potential adverse renal events from bisphosphonates.
The Oncologist Symptom Management and Supportive Care Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastases JAMES R. BERENSON On behalf of the Monterey Zoledronic Acid Advisory
More informationZerlinda (MRP DK/H/2265/001)
Zerlinda (MRP DK/H/2265/001) VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Prevention of bone complications, e.g. fractures, in adult patients with bone metastases (spread
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationAnalysis of Denosumab on Skeletal-Related Events in Patients With Advanced Breast Cancer
Downloaded on 12 07 2018. Single-user license only. Copyright 2018 by the Oncology Nursing Society. For permission to post online, reprint, adapt, or reuse, please email pubpermissions@ons.org Online Exclusive
More informationBISPHOSPHONATES ARE POTENT INHIBITORS of normal and. A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer Patients
JOURNAL OF BONE AND MINERAL RESEARCH Volume 14, Number 9, 1999 Blackwell Science, Inc. 1999 American Society for Bone and Mineral Research A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer Patients
More informationZoledronic acid in the management of metastatic bone disease
REVIEW Zoledronic acid in the management of metastatic bone disease Thomas J Polascik Vladimir Mouraviev Duke Prostate Center and Division of Urologic Surgery, Duke University Medical Center, Durham, NC,
More informationPublished Ahead of Print on May 2, 2009 as /theoncologist
The Oncologist Symptom Management and Supportive Care High Incidence of Hypocalcemia and Serum Creatinine Increase in Patients with Bone Metastases Treated with Zoledronic Acid MONICA ZURADELLI, a GIOVANNA
More informationClodronate BE/H/PSUR/001/001 October 2011 Agreed CSP
Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Intravenous use Treatment of hypercalcemia due to malignancy. Oral use Treatment of hypercalcemia
More informationHOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationSetting The study setting was secondary care. The economic study was undertaken in Spain.
Zoledronic acid versus pamidronate: cost minimisation in bone metastasis Slof J, Badia X, Lizan L, Bautista F J, Echarri E, Hurle A D, Pla R, Mangues M A, Rodriguez-Sasiain J M, Wood M A Record Status
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationOncologist. The. Symptom Management and Supportive Care. Bisphosphonates in Oncology: Rising Stars or Fallen Heroes
The Oncologist Symptom Management and Supportive Care Bisphosphonates in Oncology: Rising Stars or Fallen Heroes TIM VAN DEN WYNGAERT, a,b MANON T. HUIZING, a ERIC FOSSION, c JAN B. VERMORKEN a a Department
More informationBone resorption predicts for skeletal complications in metastatic bone disease
British Journal of Cancer (2003) 89, 2031 2037 All rights reserved 0007 0920/03 $25.00 www.bjcancer.com Bone resorption predicts for skeletal complications in metastatic bone disease JE Brown 1, CS Thomson
More informationZoledronic Acid Is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients with at Least One Osteolytic Lesion
36 Zoledronic Acid Is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients with at Least One Osteolytic Lesion Lee S. Rosen, M.D. 1 David H. Gordon, M.D. 2 William
More informationManaging Skeletal Metastases
Managing Skeletal Metastases Alison Stopeck, M.D. Professor of Medicine Director, Breast Cancer Program University of Arizona Cancer Center Tucson, AZ Disclosures: Consulting, research funding, and honoraria
More informationAppendix D Clinical specialist statement template
Denosumab for the treatment of bone metastases from solid tumours Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare
More informationThe management and treatment options for secondary bone disease. Dr Jason Lester Clinical Oncologist Velindre Cancer Centre
The management and treatment options for secondary bone disease Dr Jason Lester Clinical Oncologist Velindre Cancer Centre Aims Overview of bone metastases management in castrate-refractory prostate cancer
More informationThe management and treatment options for secondary bone disease. Omi Parikh July 2013
The management and treatment options for secondary bone disease Omi Parikh July 2013 Learning Objectives: The assessment and diagnostic process of patients with suspected bone metastases e.g bone scan,
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationCara B. Gonzales, DDS, PhD. Assistant Professor Department of Comprehensive Dentistry UTHSCSA Dental School
Cara B. Gonzales, DDS, PhD Assistant Professor Department of Comprehensive Dentistry UTHSCSA Dental School March 30, 2010 1 st annual STOHN Convocation 16 Community Clinicians 15 Investigators Bisphosphonate-associated
More informationMonitoring therapy and mitigating side effects
Monitoring therapy and mitigating g side effects Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Associate Professor of Medicine Harvard Medical School Issues with BP Therapy Renal
More informationOUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH NON- SMALL CELL LUNG CANCER AND BONE METASTASES
ISSN: 1312-773X (Online) DOI: 10.5272/jimab.2013191.391 Journal of IMAB - Annual Proceeding (Scientific Papers) 2013, vol. 19, issue 1 OUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationOSTEONECROSIS OF THE JAW BONES IN PATIENTS TREATED WITH BISPHOSPHONATES FOR MULTIPLE MYELOMA
CASE SERIES OSTEONECROSIS OF THE JAW BONES IN PATIENTS TREATED WITH BISPHOSPHONATES FOR MULTIPLE MYELOMA F A VOHRA, M A SHEIKH ABSTRACT Key words Bisphosphonates, particularly those administered through
More informationSource of effectiveness data The effectiveness evidence was derived from a single study that was identified from a review of the literature.
Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK Guest J F, Clegg J P, Davie A M, McCloskey E Record Status This is a critical
More informationProduct: Denosumab (AMG 162) Abbreviated Clinical Study Report: (Extension Phase Results) Date: 24 August 2010 Page Page 2 of 2 of
Product: Denosumab (MG 162) bbreviated Clinical Study Report: 20040114 (Extension Phase Results) Date: 24 ugust 2010 Page Page 2 of 2 of 1314 55 2. SYNOPSIS Name of Sponsor: mgen Inc. Name of Finished
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationBisphosphonates and RANK-L inhibitors in Myeloma
Bisphosphonates and RANK-L inhibitors in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationBMJ Open. For peer review only - Journal: BMJ Open. Manuscript ID: bmjopen
Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a metaanalysis of randomized clinical trials Journal: BMJ Open Manuscript ID: bmjopen-0-00 Article
More informationDENOSUMAB. . Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB. RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer
DENOSUMAB. Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer. Peter Harper Guy s, King s & St Thomas & Leaders in
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationOsteooncology and Bone Health
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Osteooncology and Bone Health Osteooncology and Bone Health Versions 2002 2017: Bischoff / Böhme / Brunnert / Dall / Diel /
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationOsteonecrosis of the jaw (ONJ)
Osteonecrosis of the jaw (ONJ) This Infosheet explains what osteonecrosis of the jaw (ONJ) is, a rare condition related to long-term treatment with drugs known as bisphosphonates. What is ONJ? ONJ is a
More informationKey Words. Breast cancer Elderly Metastatic
The Oncologist Breast Cancer Use of Intravenous Bisphosphonates in Older Women with Breast Cancer SHARON H. GIORDANO, a SHENYING FANG, a ZHIGANG DUAN, b YONG-FANG KUO, c GABRIEL N. HORTOBAGYI, a JAMES
More informationImpact of zoledronic acid on control of metastatic spinal cord compression
Strahlenther Onkol 2012 188:910 916 DOI 10.1007/s00066-012-0158-4 Received: 16 May 2012 Accepted: 30 May 2012 Published online: 18. August 2012 Springer-Verlag 2012 D. Rades 1 S.G. Hakim 2 A. Bajrovic
More informationCommon Prescription mg/ day mg/ day mg/day
Table 19.1. Medical Management of Burning Mouth Syndrome Medications Examples of Agents Dosage Common Prescription Tricyclic antidepressants Amitryptyline (Elavil ) 10 150 mg/ day 10 mg at bedtime; increase
More informationGUIDELINES FOR THE TREATMENT OF CANCER ASSOCIATED HYPERCALCAEMIA
GUIDELINES FOR THE TREATMENT OF CANCER ASSOCIATED HYPERCALCAEMIA 22.1 GENERAL PRINCIPLES The normal range for the serum corrected calcium or albumin-adjusted calcium is 2.2-2.6mmol/l. 1 Most laboratories
More informationFYI ONLY Generic Name. Generics available. zoledronic acid N/A
Criteria Document: Reference #: PC/A011 Page 1 of 5 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community
More informationManagement of complications and side-effects of myeloma. Jackie Quinn Myeloma CNS Belfast Trust
Management of complications and side-effects of myeloma Jackie Quinn Myeloma CNS Belfast Trust Common problems in myeloma Myeloma-related complications/symptoms Treatment-related side-effects Myeloma bone
More informationNorton L et al. Nature Med 2006
New Bone Targeting Agents Ana Maria Gonzalez-Angulo, M.D. Associate Professor Section Chief, Clinical Research and Drug Development Breast Medical Oncology Systems Biology Padua, Italy 11/2012 Outline
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationQuarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
REVIEW Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women Philip Sambrook University of Sydney, Sydney Correspondence: Philip Sambrook Kolling Institute, Royal
More informationChun-Jing Geng, 1 Qian Liang, 2 Jian-Hong Zhong, 3 Min Zhu, 1 Fan-Ying Meng, 4 Ning Wu, 1 Rui Liang, 1 Bin-Yi Yuan 5
To cite: Geng C-J, Liang Q, Zhong J-H, et al. Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials. BMJ
More informationManaging Bone Pain in Metastatic Disease. Rachel Schacht PA-C Medical Oncology and Hematology Associates Presented on 11/2/2018
Managing Bone Pain in Metastatic Disease Rachel Schacht PA-C Medical Oncology and Hematology Associates Presented on 11/2/2018 None Disclosures Managing Bone Pain in Metastatic Disease This lecture will
More informationIdentification of the Risk Factors of Bone Metastatic among Breast Cancer Women in Al-Bashir Hospital
Advances in Breast Cancer Research, 2018, 7, 120-129 http://www.scirp.org/journal/abcr ISSN Online: 2168-1597 ISSN Print: 2168-1589 Identification of the Risk Factors of Bone Metastatic among Breast Cancer
More informationName of Policy: Boniva (Ibandronate Sodium) Infusion
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
More informationA Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma Fred Saad, Donald M. Gleason, Robin Murray, Simon Tchekmedyian, Peter Venner,
More informationKey words: Bisphosphonates, guidelines, drug use evaluation, breast cancer
DO PHYSICIA FOLLOW SYSTEMIC TREATMENT AND FUNDING POLICY GUIDELINES? A REVIEW OF BISPHOSPHONATE USE IN PATIENTS WITH BONE METASTASES FROM BREAST CANCER Mark Clemons 1, Katherine Enright 1, Annemarie Cesta
More informationSerial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression
european urology 52 (2007) 1381 1387 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 35 DECEMBER 10 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast
More informationIncidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates
Basic research Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates Marcin Kos Department of Maxillofacial Surgery, Klinikum Minden, Minden,
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationTalib A. Najjar, DMD, MDS, PhD Professor Oral & Maxillofacial Surgery Rutgers University
Talib A. Najjar, DMD, MDS, PhD Professor Oral & Maxillofacial Surgery Rutgers University 1 Biochemistry Interaction with Oral & Systemic Diseases Periodontal disease Jaw Bone Necrosis due to Bisphosphonate
More informationAdjuvant bisphosphonates: our recommendations
Adjuvant bisphosphonates: our recommendations Andreas Makris Mount Vernon Cancer Centre OPTIMA launch meeting, 27 April 2017 Breast Cancer Metastasis Tumour cell colonisation of bone Tumour cell proliferation
More informationBone targeting: bisphosphonates, RANK-ligands and radioisotopes. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Bone targeting: bisphosphonates, RANK-ligands and radioisotopes Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee
More informationQuando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata
Quando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata Igor A. Protzner Morbeck, MD, MSc Professor de Medicina Universidade Católica de Brasília Oncologista Clínico Onco-Vida Brasília-DF
More informationCT-guided percutaneous pedicle screw fixation followed by cementoplasty in the treatment of metastatic spinal disease
CT-guided percutaneous pedicle screw fixation followed by cementoplasty in the treatment of metastatic spinal disease Claudio Pusceddu Dpt of Interventional Radiology Oncological Hospital AOBrotzu Cagliari
More informationCost-effectiveness of Oral Clodronate Compared with Oral Ibandronate, Intravenous Zoledronate or Intravenous Pamidronate in Breast Cancer Patients
The Journal of International Medical Research 2008; 36: 400 413 Cost-effectiveness of Oral Clodronate Compared with Oral Ibandronate, Intravenous Zoledronate or Intravenous Pamidronate in Breast Cancer
More informationManagement of Bone Metastases in Breast Cancer Allan Lipton, MD Address Penn State University, Milton S. Hershey Medical Center, College of Medicine,
Management of Bone Metastases in Breast Cancer Allan Lipton, MD Address Penn State University, Milton S. Hershey Medical Center, College of Medicine, 500 University Drive, Hershey, PA 17033, USA. E-mail:
More informationBisphosphonates and Breast Cancer
Bisphosphonates and Breast Cancer Bisphosphonates Analogues of pyrophosphate Carbon substitution makes them resistant to endogenous phosphatases in circulation Potent inhibitors of osteoclast growth, maturation
More informationOncologist. The. Symptom Management and Supportive Care
The Oncologist Symptom Management and Supportive Care Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate
More informationManagement of the complications of myeloma and side-effects of treatment Christine Morris Clinical Nurse Specialist in Myeloma Royal Derby Hospital
Management of the complications of myeloma and side-effects of treatment Christine Morris Clinical Nurse Specialist in Myeloma Royal Derby Hospital Common problems in myeloma Myeloma-related complications/symptoms
More informationla Cura dei Tumori, Meldola, Italy; b Oral Surgery and Dentistry Department, Otorhinolaryngology Unit, Morgagni Pierantoni Hospital, Forlì, Italy
The Oncologist Symptom Management and Supportive Care Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study TONI IBRAHIM, a FRANCESCA BARBANTI, b
More informationLes toxicités du cancer: l os. Matti S. Aapro Cancer Center Genolier Switzerland
1 Les toxicités du cancer: l os Matti S. Aapro Cancer Center Genolier Switzerland COI Dr Aapro is/was a consultant for Amgen, BMS, Celgene, Clinigen, Eisai, Genomic Health, GSK, Helsinn, Hospira, JnJ,
More informationSpinal cord compression as a first presentation of cancer: A case report
J Pain Manage 2013;6(4):319-322 ISSN: 1939-5914 Nova Science Publishers, Inc. Spinal cord compression as a first presentation of cancer: A case report Nicholas Lao, BMSc(C), Michael Poon, MD(C), Marko
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationUse of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients
(2004) 7, 350 354 & 2004 Nature Publishing Group All rights reserved 1365-7852/04 $30.00 www.nature.com/pcan Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate
More informationQuestions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss. A Publication of The Bone and Cancer Foundation
Questions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss A Publication of The Bone and Cancer Foundation Contents This publication includes important information about
More information